Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
We report a case of metastatic renal cell carcinoma in the native kidney of a renal transplant recipient. The patient was a 57-year-old man in whom a tumor in the native kidney and bone metastasis were found incidentally on imaging, 10 years after cadaveric renal transplantation. Interferon-alpha was administered after nephrectomy and following palliative irradiation of the metastasis, but could not be continued because of allograft dysfunction. Subsequent administration of zoledronic acid and sorafenib stabilized the disease for 18 months after nephrectomy. This is the first reported case of sorafenib administration to a renal transplant recipient with metastatic renal cell carcinoma.
Hasegawa
Yasuhisa
Y
Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Minami-ku, Hiroshima, Japan. yasuhase@hiroshima-u.ac.jp
Mita
Koji
K
Matsubara
Akio
A
Ohdan
Hideki
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D004164:Diphosphonates / Q000008:administration & dosage; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D033162:Incidental Findings; D016898:Interferon-alpha / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D001557:Benzenesulfonates; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077211:Zoledronic Acid; D000077157:Sorafenib